SLC5A2 and chronic kidney disease: Post hoc analyses of randomized controlled trials of SGLT2 inhibitors in participants with T2D and high CVD risk have demonstrated improvements in cardiorenal outcomes irrespective of baseline KDIGO risk category (i.e., including participants who did not have CKD at baseline, as diagnosed by eGFR or UACR criteria) [80, 81, 82].